516 related articles for article (PubMed ID: 33162818)
1. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence
Ding M; Bu X; Li Z; Xu H; Feng L; Hu J; Wei X; Gao J; Tao Y; Cai B; Liu Y; Qu X; Shen L
Int J Biol Sci; 2020; 16(16):3100-3115. PubMed ID: 33162818
[No Abstract] [Full Text] [Related]
2. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
3. LncRNA
Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
[TBL] [Abstract][Full Text] [Related]
4. Lobetyolin inhibits the proliferation of breast cancer cells
Chen Y; Tian Y; Jin G; Cui Z; Guo W; Zhang X; Liu X
Hum Exp Toxicol; 2021 Dec; 40(12):2074-2086. PubMed ID: 34075790
[TBL] [Abstract][Full Text] [Related]
5. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
[TBL] [Abstract][Full Text] [Related]
6. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
7. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
8. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
9. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
10. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
11. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.
Ren P; Yue M; Xiao D; Xiu R; Gan L; Liu H; Qing G
J Pathol; 2015 Jan; 235(1):90-100. PubMed ID: 25142020
[TBL] [Abstract][Full Text] [Related]
12. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
[TBL] [Abstract][Full Text] [Related]
13. NDRG2 suppresses proliferation, migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells through regulating the AKT/XIAP signaling pathway.
Yang CL; Zheng XL; Ye K; Ge H; Sun YN; Lu YF; Fan QX
Int J Biochem Cell Biol; 2018 Jun; 99():43-51. PubMed ID: 29530788
[TBL] [Abstract][Full Text] [Related]
14. Ablation of the
Bröer A; Gauthier-Coles G; Rahimi F; van Geldermalsen M; Dorsch D; Wegener A; Holst J; Bröer S
J Biol Chem; 2019 Mar; 294(11):4012-4026. PubMed ID: 30635397
[TBL] [Abstract][Full Text] [Related]
15. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
Teixeira E; Silva C; Martel F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
[TBL] [Abstract][Full Text] [Related]
16. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
Cardoso HJ; Figueira MI; Vaz CV; Carvalho TMA; Brás LA; Madureira PA; Oliveira PJ; Sardão VA; Socorro S
Cell Oncol (Dordr); 2021 Apr; 44(2):385-403. PubMed ID: 33464483
[TBL] [Abstract][Full Text] [Related]
17. Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression.
Lee DG; Lee SH; Kim JS; Park J; Cho YL; Kim KS; Jo DY; Song IC; Kim N; Yun HJ; Park YJ; Lee SJ; Lee HG; Bae KH; Lee SC; Shim S; Kim YM; Kwon YG; Kim JM; Lee HJ; Min JK
J Hepatol; 2015 Dec; 63(6):1429-39. PubMed ID: 26292259
[TBL] [Abstract][Full Text] [Related]
18. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
Li D; Mei H; Pu J; Xiang X; Zhao X; Qu H; Huang K; Zheng L; Tong Q
Mol Cancer; 2015 Feb; 14():47. PubMed ID: 25889839
[TBL] [Abstract][Full Text] [Related]
19. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.
Bungard CI; McGivan JD
Biochem J; 2004 Aug; 382(Pt 1):27-32. PubMed ID: 15175006
[TBL] [Abstract][Full Text] [Related]
20. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Bröer A; Rahimi F; Bröer S
J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
